Zydus Wellness FY26: ₹1,972 Million Profit, ₹1.20 Dividend Proposed; Standalone Dip

CONSUMER-PRODUCTS
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Zydus Wellness FY26: ₹1,972 Million Profit, ₹1.20 Dividend Proposed; Standalone Dip
Overview

Zydus Wellness announced its audited FY26 results, posting consolidated profit after tax of ₹1,972 million on revenues of ₹39,400 million. The Board recommended a final dividend of ₹1.20 per share. While consolidated numbers show growth, standalone performance saw a dip.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Zydus Wellness Reports ₹1,972 Million Profit for FY26, Proposes Dividend

Zydus Wellness reported consolidated revenue of ₹39,400 Million for the financial year ended March 31, 2026. Consolidated profit after tax stood at ₹1,972 Million.

Financial Results Filing

The Board of Directors approved the audited financial results for the fiscal year ending March 31, 2026. On a standalone basis, revenue was ₹5,284 Million, with profit after tax (PAT) at ₹376 Million. The Board recommended a final dividend of ₹1.20 per equity share, representing a 60% payout ratio, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

The company's financial statements received an unmodified audit opinion. Separately, the company noted its trading window for dealing in its securities will remain closed until May 20, 2026, reopening on May 21, 2026.

Significance of Results

The results show a contrast between consolidated and standalone performance. Consolidated figures point to steady growth driven by acquisitions and brand strength, while standalone financials indicate pressures in certain segments. The dividend recommendation offers shareholders a direct return, signaling management confidence.

Company Background

Zydus Wellness significantly expanded its presence in the Indian consumer space following its acquisition of Heinz India's consumer wellness business in 2019. This strategic move brought popular brands like Complan, Sugar Free, and Nycil under its umbrella, enhancing its market share in key categories.

What Investors Should Note

Shareholders can expect a dividend of ₹1.20 per share, pending AGM approval. The company manages a diverse portfolio, integrating acquired brands while focusing on core segments. Investors will closely watch the drivers of consolidated growth against standalone segment trends.

Potential Risks

No specific risks were detailed in the company's filing.

Competitive Landscape

Zydus Wellness operates in the competitive Indian FMCG and consumer wellness sector. Its peers include major companies like Hindustan Unilever Ltd., ITC Ltd., Dabur India Ltd., and Godrej Consumer Products Ltd. These companies navigate evolving consumer preferences and market dynamics, focusing on brand building and distribution.

Performance Metrics: FY25 vs FY26

  • Consolidated revenue grew from ₹39,025 Million in FY25 to ₹39,400 Million in FY26.
  • Consolidated profit after tax increased from ₹1,919 Million in FY25 to ₹1,972 Million in FY26.
  • Standalone revenue decreased from ₹5,600 Million in FY25 to ₹5,284 Million in FY26.
  • Standalone profit after tax declined from ₹526 Million in FY25 to ₹376 Million in FY26.

Key Next Steps

Key next steps include shareholder approval of the final dividend at the August 4, 2026 AGM. Investors will await management commentary on the standalone performance dip and improvement strategies, alongside future growth drivers, new launches, and market expansion plans. Performance trends of key brands such as SugarFree, Nycil, Complan, and Glucon-D will also be closely tracked.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.